Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus

[Sally Furniss]

Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.

<!--AuthorList-->Medeiros R, Rameix-Welti MA, Lorin V, Ribaud P, Manuguerra JC, Socie G, Scieux C, Naffakh N, van der Werf S.
Unit? de G?n?tique Mol?culaire des Virus Respiratoires, URA CNRS 1966, Universit? Paris 7 EA302, Centre National de R?f?rence du virus influenzae (R?gion Nord), Institut Pasteur, Paris, France.
Influenza A viruses are responsible for significant morbidity and mortality after bone marrow transplantation. Here we report failure of inhaled zanamivir treatment in a bone-marrow transplant recipient with pneumonia caused by an influenza A (H1N1) virus, although the influenza viruses isolated from bronchoalveolar lavages before and after treatment were clearly found to be sensitive to zanamivir using cell-based and enzymatic assays. Subsequent oral treatment with oseltamivir allowed complete recovery. Poor bioavailability of zanamivir in the peripheral lungs might have been limiting treatment efficacy in such an immunocompromised patient.
http://www.ncbi.nlm.nih.gov/pubmed/17668567

 

[tropical]

Re: Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus

#1:
"Here we report failure of inhaled zanamivir treatment in a bone-marrow transplant recipient with pneumonia caused by an influenza A (H1N1) virus, although the influenza viruses isolated from bronchoalveolar lavages before and after treatment were clearly found to be sensitive to zanamivir using cell-based and enzymatic assays.

Subsequent oral treatment with oseltamivir allowed complete recovery."

 

[Snowy Owl]

Re: Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus

Hi Tropical, vitamin D3 is a modulator, Kefir mushroom is a stabiliser, and the rest is in the site.

Snowy

 

[tropical]

Re: Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus

Hi Tropical, vitamin D3 is a modulator, Kefir mushroom is a stabiliser, and the rest is in the site.

Snowy

Hi Snowy,
I suppose that your sentence pointed for a pneumonia remedy without antivirals. If not, please correct my post in this thread.

The "rest" part, because of this changed weather hotness which prone me to less digging possible data, remains unknown for me?

P.S.
Kefir can be in the industrialized adjuvated form, or it must be from every day mushroom's liquid?
What about a (red) Cau. zone (?) mushroom which liquid give very strong immunity to the people who consume it? Can it be reached on the market under some name, or it's only a priviledge of that site population?

 

[miso]

Re: Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus

And if GSK has pulled their finger out and completed clinical trials of injectable zanamivir, that would have worked too.

Inhaled zanamavir's inability to treat systemic infection is hardly news, it's advantages are to provide concentrated NA inhibitor at the site of primary infection, (and not to flood across the blood-brain barrier making people loopy).